Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia

Journal of Clinical Oncology

Volumn 27, Issue 26, 2009, Pages 4392-4397

  Jeha, Sima ^a   Razzouk, Bassem ^a   Rytting, Michael ^a   Rheingold, Susan ^a   Albano, Edythe ^a   Kadota, Richard ^a   Luchtman Jones, Lori ^a   Bomgaars, Lisa ^a   Gaynon, Paul ^a   Goldman, Stewart ^a   Ritchey, Kim ^a   Arceci, Robert ^a   Altman, Arnold ^a   Stine, Kimo ^a   Steinherz, Laurel ^a   Steinherz, Peter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOFARABINE; LIVER ENZYME; ADENINE NUCLEOTIDE; ANTINEOPLASTIC AGENT; ARABINONUCLEOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW BIOPSY; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CATHETER INFECTION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPOKALEMIA; HYPOTENSION; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; THROMBOCYTE; ACUTE DISEASE; DRUG RESISTANCE; METHODOLOGY; MYELOID LEUKEMIA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; RECURRENT DISEASE; REMISSION; TREATMENT OUTCOME;

ACUTE DISEASE; ADENINE NUCLEOTIDES; ADOLESCENT; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, NEOPLASM; FEMALE; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID; MALE; NAUSEA; NEUTROPENIA; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349315339     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.8706     Document Type: Article

References (32)

1. Pui C: Childhood leukemias. N Engl J Med 332:1618-1630, 1995
2. Kersey J: Fifty years of studies of the biology and therapy of childhood leukemia. Blood 90:4243-4251, 1997
3. Arceci R: Progress and controversies in the treatment of pediatric acute myelogenous leukemia. Curr Opin Hematol 9:353-360, 2002
4. Ravindranath Y: Recent advances in pediatric acute lymphoblastic and myeloid leukemia. Curr Opin Oncol 15:23-35, 2003
5. Hann I, Webb D, Gibson B, et al: MRC trials in childhood acute myeloid leukaemia. Ann Hematol 83:S108-S112, 2004
6. Stevens R, Hann I, Wheatley K, et al: Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: Results of the United Kingdom Medical Research Council's 10th AML trial. Br J Haematol 101:130-140, 1998
7. Webb D, Wheatley K, Harrison G, et al: Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. Leukemia 13:25-31, 1999
8. Wells R, Adams M, Alonzo T, et al: Mitoxantrone and cytarabine induction, high dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group study 2951. J Clin Oncol 21:2940-2947, 2003
9. McCarthy A, Pitcher L, Hann I, et al: FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children. Med Pediatr Oncol 32:411-415, 1999
10. Aladjidi N, Auvrignon A, Leblanc T, et al: Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol 21:4377-4385, 2003
11. Hirschfeld S, Ho P, Smith M, et al: Regulatory approvals of pediatric oncology drugs: Previous experience and new initiatives. J Clin Oncol 21:1066-1073, 2003
12. Månsson E, Flordal E, Liliemark J, et al: Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem Pharm 65:237-247, 2003
13. Yamauchi T, Nowak B, Keating M, et al: DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 7:3580-3589, 2001
14. Plunkett W, Gandhi V: Purine and pyrimidine nucleoside analogs, in Giacconi G, Schilsky R, Sondel P (eds). Cancer Chemotherapy and Biological Response Modifiers Annual 19. Oxford, United Kingdom, Elsevier Science, 2001, pp 21-24
15. Parker W, Shaddix S, Rose L: Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabino-furanosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro-beta-D-ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro-beta-D-ribofuranosyl) adenine in CEM cells. Mol Pharmacol 55:515-520, 1999
16. Cheson B, Vena D, Foss F, et al: Neurotoxicity of purine analogs: A review. J Clin Oncol 12:2216-2228, 1994
17. Jeha S, Gandhi V, Chan K, et al: Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 103:784-789, 2004
18. Kantarjian H, Gandhi V, Kozuch P, et al: Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 21:1167-1173, 2003
19. Kantarjian H, Gandhi V, Cortes J, et al: Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed leukemia. Blood 102:2379-2386, 2003
20. Jeha S, Gaynon P, Razzouk B, et al: Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 24:1917-1923, 2006
21. Cheson BD, Cassileth PA, Head DR, et al: Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813-819, 1990
22. Kaplan E, Meier P: Nonparametric estimation of incomplete observations. J Am Stat Assoc 53: 457-481, 1958
23. Grimwade D, Walker H, Oliver H, et al: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92:2322-2333, 1998
24. Rubnitz J, Razzouk B, Lensing S, et al: Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer 109:157-163, 2007
25. Stahnke K, Boos J, Bender-Goetze C, et al: Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia. Leukemia 12:1534-1538, 1998
26. Abrahamsson J, Clausen N, Gustafsson G, et al: Improved outcome after relapse in children with acute myeloid leukaemia. Br J Haematol 136:229-236, 2007
27. Steinherz P, Meyers P, Steinherz L, Jeha S: Clofarabine-induced durable complete remission in heavily pretreated adolescents with relapsed and refractory leukemia. J Pediatr Hematol Oncol 29: 656-658, 2007
28. Karp J, Ricklis RM, Balakrishnan K, et al: A phase I clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 110:1762-1769, 2007
29. Hijiya N, Gaynon P, Fernandez M, et al: A novel therapy of clofarabine in combination with etoposide and cyclophosphamide shows activity in pediatric patients with refractory or relapsed acute leukemia. Blood 110:270a, 2007 (abstr 883)
30. Cooper T, Ayres M, Nowak B, and Gandhi V: Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol 55: 361-368, 2005
31. Faderl S, Verstovsek S, Cortes J, et al: Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 108:45-51, 2006
32. Agura E, Berryman B, Brougher L, et al: Phase II study of clofarabine and cytosine arabinoside in adult patients with relapsed AML and in elderly patients with untreated AML who are at high risk of anthracycline toxicity. Blood 108:552a, 2006 (abstr 1951)